Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case Report
| Autor: | Daniel Vidacek, Frank Lammert, Simone Zimmermann, Marcin Krawczyk |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Liver Cirrhosis
Male Cancer Research medicine.medical_specialty Metastatic Urothelial Carcinoma Cirrhosis medicine.medical_treatment Catumaxomab Gastroenterology Internal medicine Antibodies Bispecific Ascites Paracentesis Carcinoma Humans Medicine Aged Chemotherapy Urinary bladder medicine.diagnostic_test business.industry Hematology General Medicine medicine.disease Treatment Outcome medicine.anatomical_structure Urinary Bladder Neoplasms Oncology medicine.symptom business Injections Intraperitoneal medicine.drug |
| Zdroj: | Onkologie. 35:592-594 |
| ISSN: | 1423-0240 0378-584X |
| DOI: | 10.1159/000342670 |
| Popis: | Background: Refractory malignant ascites is a common complication in tumor patients. To date, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Lately, intraperitoneal therapy with catumaxomab, a trifunctional hybrid antibody, has been introduced for the treatment of malignant ascites, and its utility has been demonstrated in patients with distinct abdominal malignancies. Case Report: We report the first case of successful catumaxomab treatment of malignant ascites in a patient with advanced carcinoma of the urinary bladder and liver cirrhosis. Although at admission a largevolume paracentesis was needed every other day, paracentesis was no longer necessary after catumaxomab therapy. Conclusion: Catumaxomab might represent a safe treatment option for malignant ascites in the course of metastatic urothelial carcinoma, also in the setting of liver cirrhosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|